Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy

被引:28
|
作者
Sarihan, S [1 ]
Ercan, I
Saran, A
Çetintas, SK
Akalin, H
Engin, K
机构
[1] Uludag Univ, Fac Med, Dept Radiat Oncol, TR-16059 Bursa, Turkey
[2] Uludag Univ, Fac Med, Dept Biostat, TR-16059 Bursa, Turkey
[3] AOS Oncol Hosp, Dept Radiat Oncol, Bursa, Turkey
[4] Uludag Univ, Fac Med, Dept Microbiol & Infect Dis, TR-16059 Bursa, Turkey
来源
CANCER DETECTION AND PREVENTION | 2005年 / 29卷 / 02期
关键词
non-small cell lung cancer; radiotherapy; infection; predisposing factors;
D O I
10.1016/j.cdp.2004.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We aim to determine infections occuring in patients with non-small cell lung cancer during radiotherapy (RT). Methods and materials: A total of 181 patients had been treated with thoracic radiotherapy between October 1995 and December 1999. Radiotherapy was given using 1.8-3 Gray (Gy) fraction daily, five fractions a week for a total dose of 59.4 Gy (30-70.2 Gy). A complete history was collected retrospectively for each patient. All microbiological examinations were performed according to the routine procedures of the hospital laboratory. Numeric and categoric variables were employed such as sex, age, performance status, histology, stage, chemotherapy, usage of corticosteroids, neutropenia, surgery, hospitalization, associated diseases, smoking during treatment, package per year of cigarette smoking, dose of radiotherapy, and response rates. Results: Infections developed in 84 patients (46%, 84/181) during thoracic radiotherapy. A 101 episodes of infections developed in these patients. Most patients suffered from sputum production (65%), cough (59%), auscultation findings (31%) and fever (31%). Gram-negative bacteria were the most frequently isolated pathogens in the cultures of specimens (70%, 16/23 samples). Neoadjuvant chemotherapy (OR = 4.81; 95% CI, 1.57-9.12; p = 0.003) and neutropenia (OR = 4.25; 95% CI, 1.44-6.89; p = 0.009) were found as risk factors for influencing infection based on logistic regression analyses. Package per year of cigarette smoking was found statistically significantly higher in patients with infections than patients without infections (p = 0.001). A slight increase in infections, which was of borderline statistical significance (p = 0.07), was observed in patients age over 70. Ciprofloxacin and clarithromycin were the most frequently used agents in treatment. Median survival was 9 months in the patients with infection and 13 months in the 97 patients without infection. Overall survival seemed to be statistically significantly better in patients without infection than patients with infection (p = 0.042) calculated using Kaplan-Meier method. Based on Cox regression analyses; overall survival was not correlated to presence of infection but associated with poor performance status (<= 80) (OR = 2.35; 95% CI, 0.85-8.93; p = 0.03), and usage of corticosteroids (OR=2.68; 95% CI, 0.98-6.72; p = 0.01). The dose of radiation therapy > 5940 cGy (OR = 2.06; 95% CI, 0.72-7.18; p = 0.007) and the absence of response to treatment (OR = 2.45; 95% CI, 0.89-14.23; p < 0.001) were also found to be risk factors for survival. Conclusions: Infections are important causes of morbidity and mortality in lung cancer patients. The control of infection in these patients may improve the survival. Predisposing factors and treatment management approaches in non-small cell lung cancer should be defined carefully. (c) 2004 International Society for Preventive Oncology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 50 条
  • [31] Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy
    Klement, Rainer J.
    Sonke, Jan-Jakob
    Allgaeuer, Michael
    Andratschke, Nicolaus
    Appold, Steffen
    Belderbos, Jose
    Belka, Claus
    Dieckmann, Karin
    Eich, Hans T.
    Flentje, Michael
    Grills, Inga
    Eble, Michael
    Hope, Andrew
    Grosu, Anca L.
    Semrau, Sabine
    Sweeney, Reinhart A.
    Hoerner-Rieber, Juliane
    Werner-Wasik, Maria
    Engenhart-Cabillic, Rita
    Ye, Hong
    Guckenberger, Matthias
    RADIOTHERAPY AND ONCOLOGY, 2020, 142 : 210 - 216
  • [32] EVALUATION OF A COMPOSITE IMMUNOTHERAPY SIGNATURE IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ATEZOLIZUMAB
    Tolba, Khaled
    Gandara, David
    Montesion, Meagan
    Nabet, Barzin
    Srivastava, Minu
    Albacker, Lee
    Redman, Mary
    Kozono, David
    Cummings, Craig
    Herbst, Roy
    Shames, David
    Fabrizio, David
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A611 - A611
  • [33] Stereotactic radiotherapy for brain metastasis in patients with non-small cell lung cancer
    Nagaraja, S.
    Hueltenschmidt, B.
    Nadji, S.
    Frank, N.
    Lindel, K.
    RADIOTHERAPY AND ONCOLOGY, 2023, 182 : S907 - S908
  • [34] Local consolidating Radiotherapy in Patients with oligometastatic Non-small cell Lung Cancer
    Fabian, Alexander
    Pyschny, Florian
    Krug, David
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (12) : 1113 - 1115
  • [35] SIMULTANEOUS RADIOTHERAPY AND CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER
    KARSTENS, JH
    ANDREOPOULOS, D
    BREMER, D
    AMMON, J
    TUMORDIAGNOSTIK & THERAPIE, 1988, 9 : 26 - 30
  • [36] Stereotactic Body Radiotherapy for Oligometastatic Non-small Cell Lung Cancer Patients
    Mascitillo, S.
    Bonucci, I.
    Menichelli, C.
    Masi, L.
    Doro, R.
    Casamassima, F.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S539 - S540
  • [37] A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients
    Ramella, Sara
    Fiore, Michele
    Greco, Carlo
    Cordelli, Ermanno
    Sicilia, Rosa
    Merone, Mario
    Molfese, Elisabetta
    Miele, Marianna
    Cornacchione, Patrizia
    Ippolito, Edy
    Lannello, Giulio
    D'Angelillo, Rolando Maria
    Soda, Paolo
    PLOS ONE, 2018, 13 (11):
  • [38] The effects of radiotherapy on the survival of patients with unresectable non-small cell lung cancer
    Tini, Paolo
    Nardone, Valerio
    Pastina, Pierpaolo
    Pirtoli, Luigi
    Correale, Pierpaolo
    Giordano, Antonio
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (06) : 593 - 602
  • [39] The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer
    Georg Holgersson
    Michael Bergqvist
    Jan Nyman
    Even Hoye
    Martin Helsing
    Signe Friesland
    Margareta Holgersson
    Lars Ekberg
    Charlotte Mörth
    Simon Ekman
    Thomas Blystad
    Sven-Börje Ewers
    Britta Löden
    Roger Henriksson
    Stefan Bergström
    Medical Oncology, 2013, 30
  • [40] The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer
    Holgersson, Georg
    Bergqvist, Michael
    Nyman, Jan
    Hoye, Even
    Helsing, Martin
    Friesland, Signe
    Holgersson, Margareta
    Ekberg, Lars
    Morth, Charlotte
    Ekman, Simon
    Blystad, Thomas
    Ewers, Sven-Borje
    Loden, Britta
    Henriksson, Roger
    Bergstrom, Stefan
    MEDICAL ONCOLOGY, 2013, 30 (01)